Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil.
Thorac Cardiovasc Surg
; 46(3): 161-2, 1998 Jun.
Article
in En
| MEDLINE
| ID: mdl-9714495
ABSTRACT
"Panel Reactive Antibody" (PRA) testing is commonly used to assess the pretransplant antibody status in order to estimate the risk of an adverse humoral response following transplantation. We report on a female patient with end-stage cardiac failure suffering from acute myocarditis who underwent implantation of a left-ventricular assist device (Novacor, Baxter Healthcare Corp. Oakland, CA). During evaluation for heart transplantation, a PRA level of 50-70% was detected. After treatment with mycophenolate mofetil at a dosage of 2 g daily, PRA levels declined within one week to 0-5%, and remained low after discontinuation of the immunosuppressive drug. We feel that pretreatment of patients with elevated PRA levels with mycophenolate mofetil is well justified.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Heart Transplantation
/
Heart Failure
/
Immunosuppressive Agents
/
Antibodies, Monoclonal
/
Mycophenolic Acid
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
Thorac Cardiovasc Surg
Year:
1998
Document type:
Article
Affiliation country:
Germany
Publication country:
ALEMANHA
/
ALEMANIA
/
DE
/
DEUSTCHLAND
/
GERMANY